Vitamin E Supplementation Effect in Management of Calcium Oxalate Crystals

July 15, 2026 updated by: Maria Aslam, University of Lahore

Comparative Effect of Different Concentrations of Vitamin E Supplementation in Management of Calcium Oxalate Crystals in Nephrolithiatic Patients

Nephrolithiasis is a condition characterized by the formation of crystalline stones in the urinary system. The most common component of these stones is calcium oxalate. The current study was proposed to explore the effect of different concentration of vitamin E supplementation on Calcium oxalate crystal among nephrolithiatic patients.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

A randomized controlled trial (pre-post treatment) was conducted on 48 participants who met the inclusion criteria. The participants were selected from the OPD of Hussain Memorial Hospital in Lahore. They were divided into three groups, with each group consisting of 16 participants. The control group (T0) did not receive any treatment, while the treatment groups received different doses of Vitamin E supplementation. The first treatment group (T1) received 200mg of Vitamin E supplementation, and the second treatment group (T2) received 400mg of Vitamin E supplementation, both for a duration of 8 weeks. Data was collected at baseline and after the 8th week of the study, including blood samples for renal function tests (RFT), ultrasounds, and 24-hour urine samples for calcium and oxalate analysis.

Study Type

Interventional

Enrollment (Actual)

48

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
      • Lahore, Pakistan
        • The University of Lahore

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Both male and female.
  • Participants between the age of 20-50 years old.
  • Presence of calcium oxalate crystals in urine and kidneys
  • The size of the stones will range from 2 to 5 mm.

Exclusion Criteria:

  • People having stones of Uric acid, struvite, Cystine.
  • People having any other medical condition (End stage renal disease, Chronic Kidney disease, Kidney failure, and dialysis) .
  • Subjects were excluded if they were taking any medications, which might affect vitamin E metabolism (such as Wrafrin, dalteparin sodium, enoxaparin sodium).
  • Pregnant and lactating females.
  • People having known allergies to Vitamin E supplementation (rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing).
  • Participants enrolled in other studies or taking other nutraceutical preparations.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Control Group T0
The control group (T0) did not receive any additional treatment except routine medications
Drug: Control Group T0
The participants were on conventional medicines
Experimental: Intervention Group T1
T1 group participants were taking 200mg/day of Vitamin E along with conventional medicines
Dietary supplement: Intervention Group T1
T1 group participants were taking 200mg/day of Vitamin E supplementation once a day along with conventional medicines
Experimental: Intervention Group T2
T2 group participants were taking 400mg/day of Vitamin E along with conventional medicines
Dietary supplement: Intervention Group T2
T2 group participants were taking 400mg/day of Vitamin E supplementation once a day along with conventional medicines

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Urine Analysis
Time Frame: 8 weeks
The laboratory reading of urine analysis involves the identification and microscopic examination of urine to assess the characteristics and concentration of calcium and oxalate crystals present.
8 weeks
Renal function test
Time Frame: 8 weeks
This involved measuring the levels of BUN (blood urea nitrogen) and creatinine in the blood.
8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Lahore

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 5, 2022

Primary Completion (Actual)

February 7, 2023

Study Completion (Actual)

April 5, 2023

Study Registration Dates

First Submitted

July 15, 2026

First Submitted That Met QC Criteria

July 15, 2026

First Posted (Actual)

July 20, 2026

Study Record Updates

Last Update Posted (Actual)

July 20, 2026

Last Update Submitted That Met QC Criteria

July 15, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IRB-UOL-FAHS/951/2022

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Nephrolithiasis

Clinical Trials on Control Group T0

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe